C1QL1
gene geneOn this page
Also known as CRFC1QRFC1QTNF14CTRP14
Summary
C1QL1 (complement C1q like 1, HGNC:24182) is a protein-coding gene on chromosome 17q21.31, encoding C1q-related factor (O75973). May regulate the number of excitatory synapses that are formed on hippocampus neurons.
Predicted to enable signaling receptor binding activity. Predicted to be involved in locomotory behavior. Predicted to act upstream of or within maintenance of synapse structure; motor learning; and neuron remodeling. Predicted to be located in several cellular components, including climbing fiber; extracellular region; and presynapse. Predicted to be part of collagen trimer. Predicted to be active in cerebellar climbing fiber to Purkinje cell synapse and synaptic cleft.
Source: NCBI Gene 10882 — RefSeq curated summary.
At a glance
- GWAS associations: 9
- Clinical variants (ClinVar): 44 total — 1 pathogenic
- MANE Select transcript:
NM_006688
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:24182 |
| Approved symbol | C1QL1 |
| Name | complement C1q like 1 |
| Location | 17q21.31 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | CRF, C1QRF, C1QTNF14, CTRP14 |
| Ensembl gene | ENSG00000131094 |
| Ensembl biotype | protein_coding |
| OMIM | 611586 |
| Entrez | 10882 |
Gene structure
Transcript identifiers
Ensembl transcripts: 2 — 2 protein_coding
ENST00000253407, ENST00000718438
RefSeq mRNA: 1 — MANE Select: NM_006688
NM_006688
CCDS: CCDS11492
Canonical transcript exons
ENST00000253407 — 2 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000854296 | 44959693 | 44960367 |
| ENSE00000854297 | 44967452 | 44968303 |
Expression profiles
Bgee: expression breadth ubiquitous, 186 present calls, max score 93.70.
FANTOM5 (CAGE): breadth broad, TPM avg 3.6959 / max 287.6817, expressed in 693 samples.
FANTOM5 promoters (3 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 166484 | 3.0294 | 639 |
| 166483 | 0.3753 | 187 |
| 166485 | 0.2912 | 153 |
Top tissues by expression
276 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| paraflocculus | UBERON:0005351 | 93.70 | gold quality |
| middle frontal gyrus | UBERON:0002702 | 92.66 | silver quality |
| Brodmann (1909) area 10 | UBERON:0013541 | 91.73 | silver quality |
| amygdala | UBERON:0001876 | 89.63 | gold quality |
| cingulate cortex | UBERON:0003027 | 88.80 | gold quality |
| anterior cingulate cortex | UBERON:0009835 | 88.80 | gold quality |
| endometrium epithelium | UBERON:0004811 | 88.73 | gold quality |
| hypothalamus | UBERON:0001898 | 87.98 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 87.97 | gold quality |
| spinal cord | UBERON:0002240 | 86.61 | gold quality |
| right frontal lobe | UBERON:0002810 | 84.30 | gold quality |
| type B pancreatic cell | CL:0000169 | 84.14 | silver quality |
| temporal lobe | UBERON:0001871 | 83.97 | gold quality |
| nucleus accumbens | UBERON:0001882 | 83.62 | gold quality |
| Ammon’s horn | UBERON:0001954 | 83.43 | gold quality |
| cerebellar vermis | UBERON:0004720 | 82.93 | gold quality |
| neocortex | UBERON:0001950 | 82.88 | gold quality |
| prefrontal cortex | UBERON:0000451 | 82.65 | gold quality |
| caudate nucleus | UBERON:0001873 | 82.60 | gold quality |
| dorsolateral prefrontal cortex | UBERON:0009834 | 82.41 | gold quality |
| frontal cortex | UBERON:0001870 | 82.38 | gold quality |
| substantia nigra | UBERON:0002038 | 82.29 | gold quality |
| cerebral cortex | UBERON:0000956 | 81.82 | gold quality |
| telencephalon | UBERON:0001893 | 81.77 | gold quality |
| midbrain | UBERON:0001891 | 81.47 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 81.30 | gold quality |
| cartilage tissue | UBERON:0002418 | 81.25 | gold quality |
| ganglionic eminence | UBERON:0004023 | 80.96 | gold quality |
| pancreatic ductal cell | CL:0002079 | 80.56 | silver quality |
| putamen | UBERON:0001874 | 80.55 | gold quality |
Single-cell (SCXA)
Detected in 6 experiment(s), a significant marker in 5.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-9435 | yes | 583.31 |
| E-MTAB-5061 | yes | 486.35 |
| E-GEOD-84465 | yes | 236.69 |
| E-GEOD-135922 | yes | 27.37 |
| E-GEOD-137537 | yes | 8.06 |
| E-ANND-3 | no | 1.54 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
34 targeting C1QL1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-9-5P | 100.00 | 72.28 | 2361 |
| HSA-MIR-6127 | 100.00 | 66.76 | 2188 |
| HSA-MIR-6129 | 100.00 | 66.46 | 2080 |
| HSA-MIR-4510 | 100.00 | 66.60 | 2050 |
| HSA-MIR-6130 | 100.00 | 66.69 | 2012 |
| HSA-MIR-6133 | 100.00 | 66.48 | 2064 |
| HSA-MIR-493-5P | 99.96 | 72.47 | 2382 |
| HSA-LET-7C-3P | 99.95 | 73.42 | 2862 |
| HSA-MIR-4731-5P | 99.89 | 67.23 | 2537 |
| HSA-LET-7A-2-3P | 99.87 | 70.53 | 1921 |
| HSA-MIR-4492 | 99.87 | 68.25 | 3611 |
| HSA-LET-7G-3P | 99.85 | 70.43 | 1929 |
| HSA-MIR-6756-5P | 99.82 | 67.97 | 2466 |
| HSA-MIR-4307 | 99.82 | 70.45 | 3374 |
| HSA-MIR-132-3P | 99.73 | 70.56 | 1424 |
| HSA-MIR-212-3P | 99.73 | 70.65 | 1424 |
| HSA-MIR-10393-3P | 99.72 | 66.56 | 961 |
| HSA-MIR-6801-5P | 99.72 | 66.50 | 981 |
| HSA-MIR-6766-5P | 99.68 | 67.70 | 2325 |
| HSA-MIR-1249-5P | 99.61 | 66.55 | 2049 |
| HSA-MIR-6797-5P | 99.61 | 66.55 | 2084 |
| HSA-MIR-762 | 99.58 | 66.61 | 1994 |
| HSA-MIR-4498 | 99.47 | 67.42 | 2360 |
| HSA-MIR-4505 | 99.27 | 67.81 | 2678 |
| HSA-MIR-133A-3P | 99.27 | 71.53 | 1270 |
| HSA-MIR-133B | 99.27 | 71.53 | 1270 |
| HSA-MIR-5787 | 99.22 | 67.86 | 2628 |
| HSA-MIR-5587-5P | 99.07 | 68.58 | 838 |
| HSA-MIR-5001-5P | 99.05 | 66.76 | 1972 |
| HSA-MIR-1910-5P | 97.42 | 66.36 | 844 |
Literature-anchored findings (GeneRIF, showing 2)
- Conserved recoding RNA editing of vertebrate C1q-related factor C1QL1. (PMID:19275900)
- We conclude that the underexpression of CRABP1 and the overexpression of LCN2 may be useful diagnostic biomarkers in thyroid tumours with questionable malignity, and the overexpression of LCN2 and C1QL1 may be useful for prognostic purposes. (PMID:29321030)
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | c1ql1 | ENSDARG00000043436 |
| mus_musculus | C1ql1 | ENSMUSG00000045532 |
| rattus_norvegicus | C1ql1 | ENSRNOG00000002963 |
Paralogs (23): C1QTNF3 (ENSG00000082196), COL19A1 (ENSG00000082293), PDCD7 (ENSG00000090470), COL10A1 (ENSG00000123500), C1QTNF6 (ENSG00000133466), C1QL2 (ENSG00000144119), COL8A1 (ENSG00000144810), C1QTNF2 (ENSG00000145861), C1QC (ENSG00000159189), C1QTNF7 (ENSG00000163145), C1QL3 (ENSG00000165985), COL8A2 (ENSG00000171812), C1QTNF4 (ENSG00000172247), C1QB (ENSG00000173369), C1QA (ENSG00000173372), C1QTNF1 (ENSG00000173918), ADIPOQ (ENSG00000181092), OTOL1 (ENSG00000182447), C1QTNF8 (ENSG00000184471), C1QL4 (ENSG00000186897), C1QTNF9B (ENSG00000205863), C1QTNF5 (ENSG00000223953), C1QTNF9 (ENSG00000240654)
Protein
Protein identifiers
C1q-related factor — O75973 (reviewed: O75973)
Alternative names: C1q and tumor necrosis factor-related protein 14, Complement component 1 Q subcomponent-like 1
All UniProt accessions (1): O75973
UniProt curated annotations — full annotation on UniProt →
Function. May regulate the number of excitatory synapses that are formed on hippocampus neurons. Has no effect on inhibitory synapses.
Subunit / interactions. Interacts with ADGRB3. Forms heterooligomers with C1QL4, when proteins are coexpressed; this interaction does not occur after secretion.
Subcellular location. Secreted.
Tissue specificity. Expressed in brainstem.
RefSeq proteins (1): NP_006679* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR001073 | C1q_dom | Domain |
| IPR008160 | Collagen | Repeat |
| IPR008983 | Tumour_necrosis_fac-like_dom | Homologous_superfamily |
| IPR050822 | Cerebellin_Synaptic_Org | Family |
Pfam: PF00386, PF01391
UniProt features (7 total): domain 2, compositionally biased region 2, signal peptide 1, chain 1, region of interest 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-O75973-F1 | 79.26 | 0.52 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 136 (showing top):
CREL_01, WANG_CLIM2_TARGETS_UP, BENPORATH_ES_WITH_H3K27ME3, GOBP_COGNITION, GOBP_BEHAVIOR, MCLACHLAN_DENTAL_CARIES_UP, PAX4_01, GOCC_COLLAGEN_TRIMER, GOBP_NEURON_MATURATION, GOBP_CELLULAR_COMPONENT_MAINTENANCE, GOBP_NEUROGENESIS, GGGTGGRR_PAX4_03, GOBP_CELL_CELL_SIGNALING, NFKB_Q6, GOBP_ANATOMICAL_STRUCTURE_MATURATION
GO Biological Process (5): locomotory behavior (GO:0007626), neuron remodeling (GO:0016322), motor learning (GO:0061743), maintenance of synapse structure (GO:0099558), regulation of synapse pruning (GO:1905806)
GO Molecular Function (2): signaling receptor binding (GO:0005102), protein binding (GO:0005515)
GO Cellular Component (7): collagen trimer (GO:0005581), cytoplasm (GO:0005737), synaptic cleft (GO:0043083), climbing fiber (GO:0044301), presynapse (GO:0098793), cerebellar climbing fiber to Purkinje cell synapse (GO:0150053), extracellular region (GO:0005576)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 4 |
| behavior | 1 |
| neuron maturation | 1 |
| learning | 1 |
| cell junction maintenance | 1 |
| synapse organization | 1 |
| regulation of synapse organization | 1 |
| synapse pruning | 1 |
| protein binding | 1 |
| binding | 1 |
| protein-containing complex | 1 |
| intracellular anatomical structure | 1 |
| extracellular region | 1 |
| axon | 1 |
| synapse | 1 |
| asymmetric, glutamatergic, excitatory synapse | 1 |
Protein interactions and networks
STRING
1156 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| C1QL1 | ADGRB3 | O60242 | 798 |
| C1QL1 | C1QTNF8 | P60827 | 492 |
| C1QL1 | C1QTNF1 | Q9BXJ1 | 490 |
| C1QL1 | C1QTNF9 | P0C862 | 468 |
| C1QL1 | COL25A1 | Q9BXS0 | 449 |
| C1QL1 | NBEAL1 | Q6ZS30 | 447 |
| C1QL1 | COL24A1 | Q17RW2 | 445 |
| C1QL1 | GLDN | Q6ZMI3 | 440 |
| C1QL1 | COL9A1 | P20849 | 439 |
| C1QL1 | CTHRC1 | Q96CG8 | 438 |
| C1QL1 | C1R | P00736 | 428 |
| C1QL1 | C1QL2 | Q7Z5L3 | 422 |
| C1QL1 | COL2A1 | P02458 | 399 |
| C1QL1 | COL15A1 | P39059 | 394 |
| C1QL1 | C1QL4 | Q86Z23 | 388 |
IntAct
70 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| C1QTNF9 | C1QTNF9B | psi-mi:“MI:0914”(association) | 0.780 |
| TRDN | TMEM223 | psi-mi:“MI:0914”(association) | 0.640 |
| TMEM30B | KLRG2 | psi-mi:“MI:0914”(association) | 0.530 |
| DEFA5 | NUDT19 | psi-mi:“MI:0914”(association) | 0.530 |
| COL10A1 | C1QL1 | psi-mi:“MI:0914”(association) | 0.530 |
| CD1E | SUSD5 | psi-mi:“MI:0914”(association) | 0.530 |
| ZACN | GPAA1 | psi-mi:“MI:0914”(association) | 0.530 |
| YKT6 | C1QL1 | psi-mi:“MI:0914”(association) | 0.530 |
| FUT3 | C1QL1 | psi-mi:“MI:0914”(association) | 0.530 |
| TMED6 | SMPD2 | psi-mi:“MI:0914”(association) | 0.530 |
| CBLN4 | C1QL1 | psi-mi:“MI:0914”(association) | 0.530 |
| ADIPOQ | C1QL1 | psi-mi:“MI:0914”(association) | 0.530 |
| LAIR2 | LAMA5 | psi-mi:“MI:0914”(association) | 0.530 |
| C1QL1 | C1QTNF8 | psi-mi:“MI:0915”(physical association) | 0.400 |
| C1QL1 | C1qtnf1 | psi-mi:“MI:0915”(physical association) | 0.400 |
| C1QL1 | C1ql2 | psi-mi:“MI:0915”(physical association) | 0.400 |
| C1qtnf9 | C1QL1 | psi-mi:“MI:0915”(physical association) | 0.400 |
| TMED6 | UPK3BL1 | psi-mi:“MI:0914”(association) | 0.350 |
| ICAM2 | NRP1 | psi-mi:“MI:0914”(association) | 0.350 |
| HTR3A | GPAA1 | psi-mi:“MI:0914”(association) | 0.350 |
| MSRB3 | SPOP | psi-mi:“MI:0914”(association) | 0.350 |
| CBLN4 | ADAM11 | psi-mi:“MI:0914”(association) | 0.350 |
| F7 | C1QL1 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (59): C1QL1 (Reconstituted Complex), C1QL1 (Affinity Capture-MS), C1QL1 (Affinity Capture-MS), C1QL1 (Affinity Capture-MS), C1QL1 (Affinity Capture-MS), C1QL1 (Affinity Capture-MS), C1QL1 (Affinity Capture-MS), C1QL1 (Affinity Capture-MS), C1QL1 (Affinity Capture-MS), C1QL1 (Affinity Capture-MS), C1QL1 (Affinity Capture-MS), C1QL1 (Affinity Capture-MS), C1QL1 (Affinity Capture-MS), C1QL1 (Affinity Capture-MS), C1QL1 (Affinity Capture-MS)
ESM2 similar proteins: A5PKD9, B1AXV0, D1LYT2, D3Z7P3, D3ZB51, D3ZE85, D3ZTX0, E9PZ19, G3MWR8, O75973, O88508, O88992, O94925, P13264, P27467, P47870, P56704, P63137, Q00961, Q01098, Q08DW9, Q12841, Q14957, Q1LZ53, Q2LMP1, Q4R766, Q4W5Z4, Q4ZJM9, Q58D84, Q5R9Y1, Q5VWW1, Q5ZIN0, Q62356, Q62632, Q6AYT7, Q6AZB0, Q6UXG2, Q76LW2, Q7RTP6, Q7Z5L3
Diamond homologs: A0A060WQA3, A5PN28, A6NHN0, B2RNN3, O75973, O88992, P02745, P02746, P08125, P0C862, P14106, P14282, P23206, P25067, P25318, P27658, P31720, P31721, P83371, P98085, P98086, Q00780, Q02105, Q03692, Q05306, Q05A80, Q06575, Q06576, Q06577, Q0II24, Q15848, Q2KIU3, Q2KIX7, Q3Y5Z3, Q4ZJM7, Q4ZJM9, Q4ZJN1, Q5E9E3, Q5FVH0, Q5RJ80
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 80 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 7 | 11.7× | 4e-04 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| monoatomic ion transmembrane transport | 6 | 18.4× | 3e-04 |
| adaptive immune response | 6 | 7.4× | 5e-03 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
44 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 1 |
| Likely pathogenic | 0 |
| Uncertain significance | 40 |
| Likely benign | 1 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (1)
| Variant ID | HGVS | Classification |
|---|---|---|
| 1342375 | NC_000017.11:g.44846894_44962103del | Pathogenic |
SpliceAI
414 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 17:44960363:CGCAC:C | acceptor_gain | 1.0000 |
| 17:44960364:GCAC:G | acceptor_gain | 1.0000 |
| 17:44960365:CAC:C | acceptor_gain | 1.0000 |
| 17:44960365:CACC:C | acceptor_gain | 1.0000 |
| 17:44960366:AC:A | acceptor_gain | 1.0000 |
| 17:44960367:CC:C | acceptor_gain | 1.0000 |
| 17:44960367:CCTG:C | acceptor_loss | 1.0000 |
| 17:44960368:CTGCG:C | acceptor_loss | 1.0000 |
| 17:44960369:T:C | acceptor_loss | 1.0000 |
| 17:44960374:G:GC | acceptor_gain | 1.0000 |
| 17:44960382:C:CT | acceptor_gain | 1.0000 |
| 17:44960385:G:T | acceptor_gain | 1.0000 |
| 17:44960368:C:CC | acceptor_gain | 0.9900 |
| 17:44960372:G:T | acceptor_gain | 0.9900 |
| 17:44960374:G:C | acceptor_gain | 0.9900 |
| 17:44960384:C:CT | acceptor_gain | 0.9900 |
| 17:44967482:A:AC | donor_gain | 0.9900 |
| 17:44967483:C:CC | donor_gain | 0.9900 |
| 17:44960365:CACCT:C | acceptor_gain | 0.9700 |
| 17:44967479:CATA:C | donor_gain | 0.9700 |
| 17:44960364:GCACC:G | acceptor_gain | 0.9600 |
| 17:44960366:ACCTG:A | acceptor_gain | 0.9600 |
| 17:44960367:CCTGC:C | acceptor_gain | 0.9600 |
| 17:44967448:CCAC:C | donor_loss | 0.9600 |
| 17:44967450:ACC:A | donor_loss | 0.9600 |
| 17:44967451:C:CT | donor_loss | 0.9600 |
| 17:44967452:C:G | donor_loss | 0.9600 |
| 17:44967557:G:A | donor_gain | 0.9600 |
| 17:44960368:C:A | acceptor_gain | 0.9500 |
| 17:44960368:C:T | acceptor_gain | 0.9400 |
AlphaMissense
1677 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 17:44960206:G:C | F253L | 1.000 |
| 17:44960206:G:T | F253L | 1.000 |
| 17:44960208:A:G | F253L | 1.000 |
| 17:44960210:C:T | G252D | 1.000 |
| 17:44960211:C:G | G252R | 1.000 |
| 17:44960214:A:G | S251P | 1.000 |
| 17:44960216:A:G | F250S | 1.000 |
| 17:44960221:G:C | S248R | 1.000 |
| 17:44960221:G:T | S248R | 1.000 |
| 17:44960223:T:G | S248R | 1.000 |
| 17:44960225:T:C | Y247C | 1.000 |
| 17:44960226:A:G | Y247H | 1.000 |
| 17:44960243:C:T | G241D | 1.000 |
| 17:44960247:G:C | H240D | 1.000 |
| 17:44960264:A:G | L234P | 1.000 |
| 17:44960276:A:T | V230D | 1.000 |
| 17:44960294:A:G | L224P | 1.000 |
| 17:44960300:A:G | L222P | 1.000 |
| 17:44960308:G:C | S219R | 1.000 |
| 17:44960308:G:T | S219R | 1.000 |
| 17:44960310:T:G | S219R | 1.000 |
| 17:44960311:G:C | N218K | 1.000 |
| 17:44960311:G:T | N218K | 1.000 |
| 17:44960314:G:C | S217R | 1.000 |
| 17:44960314:G:T | S217R | 1.000 |
| 17:44960316:T:G | S217R | 1.000 |
| 17:44960318:G:T | A216D | 1.000 |
| 17:44960324:T:A | D214V | 1.000 |
| 17:44960342:T:A | D208V | 1.000 |
| 17:44960342:T:G | D208A | 1.000 |
dbSNP variants (sampled 300 via entrez): RS1000160920 (17:44967748 C>T), RS1000236506 (17:44960029 G>A,T), RS1000903668 (17:44961340 C>T), RS1001254748 (17:44959590 T>A), RS1001322378 (17:44969873 T>G), RS1001353090 (17:44969621 C>G,T), RS1001798767 (17:44969641 G>A,C), RS1001830093 (17:44969937 A>C), RS1001940071 (17:44962437 T>G), RS1002234374 (17:44965075 C>T), RS1002312119 (17:44962104 G>C), RS1002315011 (17:44966778 T>C,G), RS1002610014 (17:44965335 A>G), RS1002614243 (17:44965252 T>C), RS1002892738 (17:44962212 A>G,T)
Disease associations
OMIM: gene MIM:611586 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
9 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST002058_13 | DNA methylation (variation) | 2.000000e-06 |
| GCST003013_13 | White matter hyperintensity burden | 1.000000e-06 |
| GCST003013_27 | White matter hyperintensity burden | 2.000000e-07 |
| GCST004412_12 | Craniofacial microsomia | 9.000000e-06 |
| GCST006585_2810 | Blood protein levels | 3.000000e-32 |
| GCST007576_242 | Chronotype | 4.000000e-10 |
| GCST008916_39 | Asthma | 8.000000e-12 |
| GCST010703_91 | Brain morphology (MOSTest) | 2.000000e-65 |
| GCST010922_12 | Hip bone mineral density and total body fat mass (bivariate analysis) | 5.000000e-09 |
EFO canonical traits (5, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0022599 | DNA methylation |
| EFO:0005665 | white matter hyperintensity measurement |
| EFO:0008328 | chronotype measurement |
| EFO:0004346 | neuroimaging measurement |
| EFO:0007702 | hip bone mineral density |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
28 total (human), top 28 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Valproic Acid | affects expression, increases expression, increases methylation | 4 |
| Benzo(a)pyrene | affects methylation, decreases methylation, increases expression, increases methylation | 3 |
| sodium arsenite | decreases expression, increases abundance, increases expression | 2 |
| Resveratrol | affects cotreatment, increases expression, decreases expression | 2 |
| Copper | increases expression, affects cotreatment, affects binding | 2 |
| Particulate Matter | increases abundance, decreases expression | 2 |
| aristolochic acid I | decreases expression | 1 |
| ethyl-p-hydroxybenzoate | decreases expression | 1 |
| arsenite | increases methylation | 1 |
| sulforaphane | decreases expression | 1 |
| abrine | decreases expression | 1 |
| 2,2’,4,4’-tetrabromodiphenyl ether | decreases expression | 1 |
| NSC 689534 | increases expression | 1 |
| Sunitinib | decreases expression | 1 |
| Acetaminophen | increases expression | 1 |
| Air Pollutants | decreases expression, increases abundance | 1 |
| Arsenic | decreases expression, increases abundance | 1 |
| Atrazine | increases expression | 1 |
| Chelating Agents | affects binding, increases expression | 1 |
| Cisplatin | decreases expression | 1 |
| Estradiol | affects cotreatment, decreases expression | 1 |
| Lead | affects expression | 1 |
| Plant Extracts | affects cotreatment, decreases expression | 1 |
| Tretinoin | decreases expression | 1 |
| Cyclosporine | decreases expression | 1 |
| Gold Compounds | decreases methylation, increases expression | 1 |
| Cadmium Chloride | increases expression | 1 |
| Okadaic Acid | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): craniofacial microsomia